BioNTech

OEM : Pharmaceutical

Website

Mainz, Rhineland-Palatinate, Germany

NASDAQ: BNTX

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.

Assembly Line

Vaccine production: Marburg has the right stuff

Date:

Topics: manufacturing execution system

Vertical: Pharmaceutical

Organizations: Siemens, BioNTech

BioNTech manufactures BNT162b2 in collaboration with US pharmaceutical specialist Pfizer. The company has started manufacturing at the production site in Marburg, in the German state of Hesse. The plant there comes with an ultramodern production facility for recombinant proteins. The relevant expertise is also available, since BioNTech also acquired a highly qualified employee base along with the production facility, all of whom are experienced in developing new technologies.

The facility in Marburg had been producing influenza vaccines based on flu cell culture, then changed over to recombinant proteins for cancer treatments and now manufactures mRNA vaccine.

All the improvements at the Marburg plant are Industry 4.0-compatible. One of the challenges with the conversion was the fact that it involved switching from rigid to mobile production with many single-use components. At the same time, working with mRNA meant a higher clean room class than was previously required in the facility. Paper is now an avoidable “contamination factor” that doesn’t arise with digital production. That was the basis for opting for the Opcenter Execution Pharma solution from Siemens as the new MES. This solution enables complete paperless manufacturing and fully electronic batch recording.

Read more at Siemens Blog

How Pfizer Makes Its Covid-19 Vaccine

Date:

Authors: Emma Cott, Elliot deBruyn, Jonathan Corum

Topics: COVID-19

Vertical: Pharmaceutical

Organizations: Pfizer, BioNTech

“This is where the magic happens.”– Patrick McEvoysenior director of operations and engineering

A rack of 16 pumps precisely controls the flow of the mRNA and lipid solutions, then mixes them together to create lipid nanoparticles.

When the lipids come into contact with the naked strands of mRNA, electric charge pulls them together in a nanosecond. The mRNA is enveloped in several layers of lipids, forming an oily, protective vaccine particle.

Synchronizing eight pairs of pumps is not an ideal solution, but Pfizer engineers chose to scale up existing technology instead of trying to build a larger, unproven type of precision mixing device.

The newly made vaccine is filtered to remove the ethanol, concentrated and filtered again to remove any impurities, and finally sterilized.

Read more at New York Times (Paid)

Politics, Science and the Remarkable Race for a Coronavirus Vaccine

Date:

Authors: Sharon LaFraniere, Katie Thomas, Noah Weiland, David Gelles, Sheryl Gay Stolberg, Denise Grady

Topics: COVID-19, mRNA

Organizations: BioNTech, Moderna, Pfizer

The furious race to develop a coronavirus vaccine played out against a presidential election, between a pharmaceutical giant and a biotech upstart, with the stakes as high as they could get.

Read more at New York Times (Paid)

The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race

Date:

Author: @damiangarde

Topics: COVID-19, mRNA

Vertical: Pharmaceutical

Organizations: BioNTech, Moderna, Pfizer

The liquid that many hope could help end the Covid-19 pandemic is stored in a nondescript metal tank in a manufacturing complex owned by Pfizer, one of the world’s biggest drug companies. There is nothing remarkable about the container, which could fit in a walk-in closet, except that its contents could end up in the world’s first authorized Covid-19 vaccine.

Pfizer, a 171-year-old Fortune 500 powerhouse, has made a billion-dollar bet on that dream. So has a brash, young rival just 23 miles away in Cambridge, Mass. Moderna, a 10-year-old biotech company with billions in market valuation but no approved products, is racing forward with a vaccine of its own. Its new sprawling drug-making facility nearby is hiring workers at a fast clip in the hopes of making history — and a lot of money.

Read more at StatNews